Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company is headquartered in Palo Alto, California.
| Revenue (TTM) | $31.61M |
| Gross Profit (TTM) | $17.54M |
| EBITDA | $-277.27M |
| Operating Margin | -385.00% |
| Return on Equity | 0.00% |
| Return on Assets | -105.80% |
| Revenue/Share (TTM) | $3.64 |
| Book Value | $-43.83 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -22.80% |
| Shares Outstanding | 0 |
| Float | $5.69M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Volatility is currently contracting
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SCLXW and any ticker you trade — then tracks every position and per-strategy win rate.